Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials

Barbara E.H. Coupar; Damian F.J. Purcell; Scott A. Thomson; Ian A. Ramshaw; Stephen J. Kent; David B. Boyle

doi:10.1016/j.vaccine.2005.09.044

Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials

Barbara E.H. Coupar, Damian F.J. Purcell, Scott A. Thomson, Ian A. Ramshaw, Stephen J. Kent, David B. Boyle^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Abstract

DNA prime and recombinant fowlpox virus (rFPV) boost vaccines were designed to express multiple HIV or SIV antigens for use in human clinical trials and in pre-clinical trials in macaques. Three sets of vaccines with matching HIV or SIV antigen sets, modified for vaccine safety considerations, were constructed and shown to express the relevant proteins. The rFPV vaccines with inserts at up to three sites, were stable on passage in chick cell culture, including during GMP manufacture of vaccines for human Phase I clinical trials. Cellular and humoral immunogenicity in mice was demonstrated using a DNA prime/rFPV boost and vaccinia virus challenge model. These data establish a preliminary safety and efficacy profile for these multigenic vaccines suggesting they are suitable for advanced development as candidate HIV vaccines.

Original language	English
Pages (from-to)	1378-1388
Number of pages	11
Journal	Vaccine
Volume	24
Issue number	9
DOIs	https://doi.org/10.1016/j.vaccine.2005.09.044
Publication status	Published - 27 Feb 2006

Access to Document

10.1016/j.vaccine.2005.09.044

Cite this

@article{5b0d98d92f3c426c9fe960cb48fb6024,

title = "Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials",

abstract = "DNA prime and recombinant fowlpox virus (rFPV) boost vaccines were designed to express multiple HIV or SIV antigens for use in human clinical trials and in pre-clinical trials in macaques. Three sets of vaccines with matching HIV or SIV antigen sets, modified for vaccine safety considerations, were constructed and shown to express the relevant proteins. The rFPV vaccines with inserts at up to three sites, were stable on passage in chick cell culture, including during GMP manufacture of vaccines for human Phase I clinical trials. Cellular and humoral immunogenicity in mice was demonstrated using a DNA prime/rFPV boost and vaccinia virus challenge model. These data establish a preliminary safety and efficacy profile for these multigenic vaccines suggesting they are suitable for advanced development as candidate HIV vaccines.",

keywords = "DNA, HIV vaccine, Prime/boost, Recombinant fowlpox virus",

author = "Coupar, {Barbara E.H.} and Purcell, {Damian F.J.} and Thomson, {Scott A.} and Ramshaw, {Ian A.} and Kent, {Stephen J.} and Boyle, {David B.}",

year = "2006",

month = feb,

day = "27",

doi = "10.1016/j.vaccine.2005.09.044",

language = "English",

volume = "24",

pages = "1378--1388",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier B.V.",

number = "9",

}

TY - JOUR

T1 - Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials

AU - Coupar, Barbara E.H.

AU - Purcell, Damian F.J.

AU - Thomson, Scott A.

AU - Ramshaw, Ian A.

AU - Kent, Stephen J.

AU - Boyle, David B.

PY - 2006/2/27

Y1 - 2006/2/27

N2 - DNA prime and recombinant fowlpox virus (rFPV) boost vaccines were designed to express multiple HIV or SIV antigens for use in human clinical trials and in pre-clinical trials in macaques. Three sets of vaccines with matching HIV or SIV antigen sets, modified for vaccine safety considerations, were constructed and shown to express the relevant proteins. The rFPV vaccines with inserts at up to three sites, were stable on passage in chick cell culture, including during GMP manufacture of vaccines for human Phase I clinical trials. Cellular and humoral immunogenicity in mice was demonstrated using a DNA prime/rFPV boost and vaccinia virus challenge model. These data establish a preliminary safety and efficacy profile for these multigenic vaccines suggesting they are suitable for advanced development as candidate HIV vaccines.

AB - DNA prime and recombinant fowlpox virus (rFPV) boost vaccines were designed to express multiple HIV or SIV antigens for use in human clinical trials and in pre-clinical trials in macaques. Three sets of vaccines with matching HIV or SIV antigen sets, modified for vaccine safety considerations, were constructed and shown to express the relevant proteins. The rFPV vaccines with inserts at up to three sites, were stable on passage in chick cell culture, including during GMP manufacture of vaccines for human Phase I clinical trials. Cellular and humoral immunogenicity in mice was demonstrated using a DNA prime/rFPV boost and vaccinia virus challenge model. These data establish a preliminary safety and efficacy profile for these multigenic vaccines suggesting they are suitable for advanced development as candidate HIV vaccines.

KW - DNA

KW - HIV vaccine

KW - Prime/boost

KW - Recombinant fowlpox virus

UR - http://www.scopus.com/inward/record.url?scp=32344445678&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2005.09.044

DO - 10.1016/j.vaccine.2005.09.044

M3 - Article

SN - 0264-410X

VL - 24

SP - 1378

EP - 1388

JO - Vaccine

JF - Vaccine

IS - 9

ER -

Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials

Abstract

Access to Document

Other files and links

Fingerprint

Cite this